Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 22 at 2:00 PM EDT

Register Free →
logo
Get CLEATUSFree Trial

Q301--T-SPOT.TB Assay Testing

Active
36C25626Q1041Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Department of Veterans Affairs, Network Contracting Office 16, intends to award a sole source, firm-fixed price purchase order to Quest Diagnostics for T SPOT.TB testing services, with the possibility of two optional extension years. The contract requires the performance of the T SPOT.TB assay, daily specimen pickup, secure transport, and full compliance with CLIA, CAP, and VA reporting standards. Quest Diagnostics is identified as the only responsible source capable of meeting all technical, regulatory, logistical, and stability requirements necessary to ensure timely and reliable testing without compromising VA screening operations. This decision is based on the unique combination of accreditation, validated assay performance, strict specimen stability windows, and daily courier logistics that no other provider can currently fulfill without introducing unacceptable risk. This notice serves as a formal announcement of intent to proceed without competition under FAR 6.302-1, but it invites interested parties to submit clear and convincing evidence demonstrating their ability to meet all requirements by July 26, 2026, at 7:00 a.m. CST. Responses must be submitted via email in Microsoft Word or PDF format to Contract Specialist William Shaver and must include documented proof of in-house assay capability, current CLIA and CAP accreditation, daily courier services, adherence to specimen stability timelines, and full compliance with VA reporting protocols. The Government will not acknowledge receipt or provide feedback on submissions, will not compensate for information provided, and retains full discretion to proceed with the sole source award regardless of any responses received. No telephone inquiries will be accepted, and this notice does not create any obligation on the part of the Government to award a contract.

General Info

Sole source award to Quest Diagnostics for T-SPOT.TB testing with optional extensions, requiring CLIA/CAP compliance and daily logistics.

Agency

Department Of Veterans Affairs → 256-NETWORK Contract Office 16 (36C256)View Agency

NAICS

621511 - Medical LaboratoriesView NAICS

Place of Performance

MS

Set-Aside

NONE

Documents

(1)

Notice of Intent to Sole Source for T-SPOT.TB Assay Testing - Solicitation 36C25626Q1041

DOCX•special-notice

AI Contract Breakdown

Uniform Contract Format

What is UCF?

Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.

Timeline

Posted

special-notice

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Veterans Affairs → 256-NETWORK Contract Office 16 (36C256)
Contacts1 person available
OfficeRIDGELAND, MS, 39157, USA
Organization / Agency
Department Of Veterans Affairs → 256-NETWORK Contract Office 16 (36C256)
View Agency Profile
Office AddressRIDGELAND, MS, 39157, USA
Contacts
William ShaverContract Specialist
contact@example.gov

Full Description

Show more
Notice of Intent to Sole Source
The Department of Veterans Affairs, Network Contracting office 16 (NCO16), intends to award a sole source, firm-fixed price open market purchase order to include two (2) option years to Quest Diagnostics, 14225 Newbrook Drive, Chantilly, VA 20151 for T SPOT.TB testing services. The required services include performance of the T SPOT.TB assay, daily specimen pickup, secure transport, and compliance with all applicable CLIA, CAP, and VA reporting requirements.
The Government intends to award this requirement to Quest Diagnostics, who is identified as the only responsible source capable of meeting all performance, regulatory, stability window, courier, and integration requirements necessary for T SPOT.TB testing. This action is being taken in accordance with FAR 6.302 1, Only One Responsible Source. Due to the unique combination of accreditation, validated assay performance, specimen stability constraints, and daily courier logistics required for timely processing of T SPOT.TB specimens, no other source has been identified that can meet all Government requirements without unacceptable risk to VA employee and patient screening operations.
This notice is not a request for competitive quotes. Interested parties who believe they can meet all requirements shall submit clear and convincing evidence, including documented proof, for Government review to determine whether competition would be advantageous to the Government. Respondents are advised that the Government is under no obligation to acknowledge receipt of submissions or provide feedback regarding any information received. Supporting documentation must be furnished in sufficient detail to demonstrate the ability to fulfill all requirements.
Responses must be received no later than July 26, 2026, 07:00 CST, demonstrating ability to perform the T SPOT.TB assay in house, maintain CLIA and CAP accreditation, provide daily courier pickup, meet strict specimen stability windows, and comply with VA reporting requirements. Responses will be evaluated; however, a determination by the Government not to compete the proposed procurement based upon responses to this notice is solely within the discretion of the Government. If no responses are received, the Government will proceed with the award. Responses shall be submitted via email in Microsoft Word or PDF format to Contract Specialist William Shaver at William.Shaver@va.gov. Telephone requests or inquiries will not be accepted. The Government will not pay for any information submitted as a result of this notice. This notice shall not be construed as an obligation on the part of the Government to acquire any products or services.

Similar Contracts

NAICS: 621511
New
Federal
Clinical Laboratory Diagnostic Testing Services – Renasight Kidney Gene TestThe contract facilitates the provision of proprietary genetic testing services through the Renasight Kidney Gene test to support the diagnosis of kidney disease among Veterans. This subcontract encompasses the full lifecycle of specimen handling, including collection, processing, genetic analysis, and the secure generation and delivery of clinical reports to authorized providers. The services are designed to enable accurate, personalized diagnostic insights for kidney-related conditions, leveraging advanced genomic technology specifically validated for this clinical application. All operations must comply with stringent data security and privacy standards to protect Veteran health information. The contract is issued under the 246-NETWORK Contracting Office 6 within the Department of Veterans Affairs and is classified under NAICS code 621511 for clinical laboratory services. It is solicited as a subcontract with a narrow response window closing on July 13, 2026, indicating an urgent need to establish or expand capacity in genomic diagnostics within the VA healthcare system. Performance is not limited to a specific geographic location, allowing the contractor to operate wherever logistical and regulatory requirements are met. There is no set-aside classification, meaning all eligible entities may compete, and the focus is on delivering reliable, timely, and clinically actionable genetic test results to improve Veteran outcomes.
246-NETWORK Contracting Office 6 (36C246)

POSTED

about 22 hours ago

DEADLINE

in 2 days
View Details
NAICS: 621511
New
Federal
Q301--Natera Renasight Test at Durham VAMCThe Department of Veterans Affairs, Network Contracting Office 6, intends to award a sole source purchase order to Natera Inc. for the provision of the Renasight kidney gene test at the Durham VA Medical Center in Durham, North Carolina. This test is exclusively offered by Natera Inc. and is intended to assist in the diagnosis of kidney disease among patients. The contract will operate under a base of service period, with no competitive bidding process initiated, as the acquisition is justified under FAR 12.102(a) for sole source procurement due to the unique and exclusive nature of the Renasight laboratory service. Although this notice does not constitute a solicitation for quotes, any business that believes it can meet the requirements with relevant expertise may submit written documentation demonstrating its capability by 10:00 a.m. EST on July 13, 2026. The Government retains full discretion to determine whether to open the acquisition to competition based on responses received. The NAICS code for this procurement is 621511, and all inquiries must be directed via email to Christian.rosadoramirez@va.gov; telephone requests are not accepted.
246-NETWORK Contracting Office 6 (36C246)

POSTED

about 22 hours ago

DEADLINE

in 2 days
View Details
NAICS: 621511
New
Federal
Q301--T-SPOT.TB Assay TestingThe Department of Veterans Affairs, Network Contracting Office 16, is pursuing a sole source procurement for T-SPOT.TB testing services under NAICS code 621511 and PSC code Q301, exclusively targeting Quest Diagnostics due to its unique and irreplaceable capability to meet all regulatory, logistical, and technical requirements. The requirement spans a base period from October 1, 2026, through September 30, 2027, with one optional one-year renewal extending through September 30, 2028, covering an estimated annual volume of 1,700 tests. Services include in-house performance of the T-SPOT.TB assay, daily Monday through Friday courier pickups from the G.V. (Sonny) Montgomery VAMC in Jackson, Mississippi, secure specimen transportation ensuring processing within the 32-hour manufacturer-specified stability window, and delivery of results within 72 hours of specimen receipt via fax to VA-specific channels with full integration into VISTA workflows and inclusion of VA identifiers (ICN or EDIPI). The contractor must maintain active CLIA and CAP accreditations covering immunologic and ELISPOT-based assays, provide certification documentation to the Jackson VAMC, and fully comply with all VA information security, privacy, and records management directives, including Title 38 U.S.C. 5705 and 7332, as well as VA Directive 0710 for personnel background investigations. All personnel must complete VA privacy training annually and sign the Contractor Rules of Behavior, with subcontractors bound by the same obligations through flow-down clauses. The government retains rights to conduct on-site inspections of IT resources and evaluate security controls, and performance will be monitored through a Quality Assurance Surveillance Plan with metrics covering service quality, turnaround time, and business relations, with final determinations resting with the Contracting Specialist. The notice, issued as a Sources Sought Notice under FAR 6.302-1, seeks evidence from other potential providers to confirm the sole source justification, with responses due by July 26, 2026, submitted electronically to William Shaver in Word or PDF format, including full technical, accreditation, security, and business size documentation such as UEI and CAGE codes. No compensation will be provided for submission of information, and the government is under no obligation to proceed with a contract based on responses received.
256-NETWORK Contract Office 16 (36C256)

POSTED

about 22 hours ago

DEADLINE

in 16 days
View Details
NAICS: 621511
New
Federal
Q301--Histology Block and Slide Processing Laboratory ServicesThe Department of Veterans Affairs, through Network Contracting Office 21, is seeking qualified vendors to provide histology tissue block and slide processing laboratory services for the Sacramento VA Medical Center. The solicitation, numbered 36C26126Q0917, will result in a single award firm fixed price indefinite delivery indefinite quantity contract, and all responses must strictly conform to the requirements outlined in the Addendum to RFO 52.212-1 and VAAR 852.273-73 to be considered eligible. Contractors must be actively registered in SAM.gov prior to award and are responsible for monitoring the system for any amendments, which must be signed and acknowledged by the vendor. The NAICS code for this requirement is 621511, and no set-aside is being used; the contract will be open to all qualified offerors. The deadline for submission is July 31, 2026, at 7:00 PM Eastern Time, and the place of performance is Mather, California, with Emily Trinh serving as the primary point of contact for inquiries.
261-NETWORK Contract Office 21 (36C261)

POSTED

about 22 hours ago

DEADLINE

in 20 days
View Details
NAICS: 621511
New
Grant
Continuing Enhanced National Surveillance for Prion Diseases in the United StatesThe Centers for Disease Control and Prevention is seeking to award funding through a cooperative agreement to sustain and enhance national surveillance for human prion diseases, also known as transmissible spongiform encephalopathies, in the United States for fiscal year 2027. The primary objective is to maintain an active, standardized system for confirming suspected cases through advanced diagnostic methods that require specialized laboratory capabilities, as definitive diagnosis of these invariably fatal conditions can only be achieved via brain tissue analysis. Many healthcare facilities lack the expertise or the infrastructure to safely handle and process such specimens due to infection control concerns, making centralized diagnostic support essential. Since 1997, CDC has supported a designated center for this purpose, enabling consistent case confirmation, tracking of disease trends, and identification of disease subtypes, all critical for public health monitoring. This continuing effort relies on a highly collaborative model, with CDC epidemiologists working closely with the funded center’s staff to interpret data, guide surveillance priorities, and evaluate potential emerging threats. The program has played a pivotal role in ensuring the reliability of national data and in confirming that novel prion disease forms, such as those potentially linked to chronic wasting disease in animals, have not emerged in the U.S. population. The funding will support state-of-the-art diagnostic techniques, personnel, laboratory operations, and ongoing data sharing mechanisms to maintain robust, nationwide surveillance. The point of contact for inquiries is Lisa Angel at the CDC’s National Center for Emerging and Zoonotic Infectious Diseases, and the solicitation is listed as a forecast with an anticipated posting date in July 2026.
Centers For Disease Control - Ncezid

POSTED

1 day ago

DEADLINE

N/A
View Details